Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $119

Benzinga Newsdesk www.benzinga.com Positive 84.4%

Neg 0% Neu 0% Pos 84.4%

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $113 to $119.